Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac.
Adaptive radiotherapy
High-field MR-linac
Interfractional motion
MR-guided radiotherapy
MR-linac
Prostate cancer
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
18
10
2019
revised:
19
04
2020
accepted:
26
04
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
13
5
2020
Statut:
epublish
Résumé
MR-guided adapted radiotherapy (MRgART) using a high field MR-linac has recently become available. We report the estimated delivered fractional dose of the first five prostate cancer patients treated at our centre using MRgART and compare this to C-Arm linac daily Image Guided Radiotherapy (IGRT). Patients were treated using adapted treatment plans shaped to their daily anatomy. The treatments were recalculated on an MR image acquired immediately prior to treatment delivery in order to estimate the delivered fractional dose. C-arm linac non-adapted VMAT treatment plans were recalculated on the same MR images to estimate the fractional dose that would have been delivered using conventional radiotherapy techniques using a daily IGRT protocol. 95% and 93% of mandatory target coverage objectives and organ at risk dose constraints were achieved by MRgART and C-arm linac delivered dose estimates, respectively. Both delivery techniques were estimated to have achieved 98% of mandatory Organ At Risk (OAR) dose constraints whereas for the target clinical goals, 86% and 80% were achieved by MRgART and C-arm linac delivered dose estimates. Prostate MRgART can be delivered using the a high field MR-linac. Radiotherapy performed on a C-arm linac offers a good solution for prostate cancer patients who present with favourable anatomy at the time of reference imaging and demonstrate stable anatomy throughout the course of their treatment. For patients with critical OARs abutting target volumes on their reference image we have demonstrated the potential for a target dose coverage improvement for MRgART compared to C-arm linac treatment.
Identifiants
pubmed: 32395640
doi: 10.1016/j.ctro.2020.04.011
pii: S2405-6308(20)30035-5
pmc: PMC7210377
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35-42Subventions
Organisme : Department of Health
ID : ICA-SCL-2018-04-ST2-002
Pays : United Kingdom
Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Radiat Oncol. 2019 Aug 6;14(1):139
pubmed: 31387593
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):785-792
pubmed: 27788951
Semin Radiat Oncol. 2014 Jul;24(3):207-9
pubmed: 24931095
Phys Med Biol. 2016 Jan 7;61(1):1-11
pubmed: 26605518
Phys Med Biol. 2011 Aug 21;56(16):5119-29
pubmed: 21775790
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1057-1060
pubmed: 30012525
Radiother Oncol. 2019 May;134:50-54
pubmed: 31005224
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1086-1094
pubmed: 31419510
Clin Transl Radiat Oncol. 2019 Apr 01;18:68-73
pubmed: 31341979
Med Phys. 2008 Aug;35(8):3607-15
pubmed: 18777921
Phys Med Biol. 2009 Jun 21;54(12):N229-37
pubmed: 19451689
Clin Transl Radiat Oncol. 2019 Apr 02;18:54-59
pubmed: 31341976
J Appl Clin Med Phys. 2019 Mar;20(3):27-36
pubmed: 30756456
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):858-866
pubmed: 30061007
Med Phys. 2011 Feb;38(2):754-64
pubmed: 21452713
Br J Radiol. 2018 Feb;91(1083):20170522
pubmed: 29166129
Phys Med Biol. 2017 Nov 14;62(23):L41-L50
pubmed: 29135471
Med Phys. 2017 Oct;44(10):5034-5042
pubmed: 28703497
Radiother Oncol. 2008 Jan;86(1):25-9
pubmed: 18023488
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Med Phys. 2018 May 28;:
pubmed: 29807390